Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial

The clinical benefit of eribulin versus capecitabine was evaluated using health-related quality of life (HRQoL) data from a phase 3 randomized trial in patients with pretreated advanced/metastatic breast cancer (ClinicalTrials.gov identifier: NCT00337103). The study population has been described pre...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Breast Cancer Res Treat
Autors principals: Cortes, Javier, Hudgens, Stacie, Twelves, Chris, Perez, Edith A., Awada, Ahmad, Yelle, Louise, McCutcheon, Susan, Kaufman, Peter A., Forsythe, Anna, Velikova, Galina
Format: Artigo
Idioma:Inglês
Publicat: Springer US 2015
Matèries:
Clinical Trial
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4661183/
https://ncbi.nlm.nih.gov/pubmed/26567010
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-015-3633-7
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars